Table II Sample distribution according to experiments and study phase
RegionUSSouth Africa
HIV statusHIV−HIV+HIV−HIV+
TB statusTB−TB+TB−TB+TB−TB+TB−TB+
Multiplex HD-NAPPA (n = 120)11211281251041
Deconvolution (n = 94)a6206765638
Validation (n = 124)b11231191261240
ELISA (n = 285)c2245462125132489
  • a Because the deconvolution of positive reactions was the prime goal of this experiment, we focused these analyses predominantly on TB+ samples from the multiplex HD-NAPPA screening.

  • b Consisting of biologically independent samples.

  • c Consisting of the original screening and validation samples (n = 244) and heretofore untested samples (n = 41).